- Ahead of the September 29 MAHA Summit, a nonprofit tied to Health and Human Services Secretary Robert F. Kennedy Jr. circulated a tiered sponsorship menu to companies and consultants, according to documents viewed by Bloomberg News and people familiar with the solicitations.
- The top tier was quoted at $300,000 to some prospective sponsors. It guaranteed a speaking slot with meaningful input on panel composition and topic, plus a private dinner for 30 guests with Kennedy and Mehmet Oz, who runs the Centers for Medicare and Medicaid Services.
- Listed sponsors on the event website include Anthropic, OpenAI, Walmart, Hims and Hers Health, Centene, Tempus AI and Compass Pathways. The most prominent logos belong to ResMed, whose chief medical officer shares a panel with NIH Director Jay Bhattacharya, and Grail, whose chief executive speaks in another session.
- Grail blood-based cancer screening test goes before a Food and Drug Administration advisory panel next week. Several other panels feature companies regulated by HHS divisions, including a psychedelics session with Compass Pathways moderated by HHS Deputy General Counsel Matt Zorn, who leads the agency psychedelics policy.
What Happened?
The MAHA Center, one of several interconnected nonprofits in Kennedy external political network, is hosting the Washington event. Maintaining an active political operation while serving in the Cabinet is unusual, and lawmakers have already questioned fundraising by Kennedy allied groups. Federal health officials also appear regularly on Zoom calls with his political supporters. Kennedy has denied speculation that he intends to run for president in 2028. HHS spokesperson Emily Hilliard said department officials listed as speakers had no involvement in planning or sponsorship activities and were unaware of the arrangements described. Administration speakers include Agriculture Secretary Brooke Rollins, HHS Principal Deputy Chief of Staff Stefanie Spear, HHS senior adviser Calley Means and Bhattacharya. Kennedy is not on the published agenda, though a placeholder exists for a conversation with special guests. Grail chief executive Josh Ofman said the company welcomes engagement with policymakers, patients and advocates and that its participation reflects a commitment to prediction, prevention and early detection. Compass Pathways said its involvement reflects a commitment to engaging wherever mental health reform is discussed. AHIP, the insurance trade group appearing on an Affordability First panel alongside Elevance Health and UnitedHealth, said it welcomes dialogue on chronic disease and affordability. MAHA Center president Tony Lyons, asked publicly on Thursday whether taking money from companies risked co-option, called it a reasonable question, did not answer it directly, and said he would like the same scrutiny applied to members of Congress.
Why It Matters?
Kennedy built his public reputation attacking the health agencies he now runs for being captured by the industries they regulate. The arrangement described here is that capture with a published price, which is the contradiction at the centre of the story. For investors the specific exposure is easier to identify than the politics. Grail is the clearest case: its chief executive speaks at an event its company sponsors, days before an FDA advisory committee reviews its central product. Whatever the panel decides, the sequence creates a disclosure and governance question that shareholders will have to weigh, and an adverse outcome now carries an additional line of criticism that has nothing to do with the science. The psychedelics panel raises the same structure in sharper form, since it is moderated by the HHS lawyer who sets the policy governing the companies on stage. The broader risk is congressional. Lawmakers have already raised concerns about this network, and a documented menu pricing access to a Cabinet secretary is the kind of specific evidence that invites hearings and document requests, which would pull sponsor companies into the process regardless of what they paid or why. Note that HHS itself has distanced its officials from the sponsorship arrangements, which leaves the companies rather than the department carrying the reputational exposure.
What Next?
The FDA advisory panel reviewing Grail cancer screening test next week is the nearest dated catalyst, and its outcome will be read against the summit sponsorship regardless of the committee reasoning. The summit itself takes place September 29, and whether Kennedy fills the special guests placeholder will indicate how directly he intends to associate himself with a paid event. Watch for congressional letters or requests for documents to MAHA Center and to individual sponsors, since the existence of a written sponsorship menu makes that a straightforward inquiry to open. Sponsor companies facing pending regulatory decisions are the ones to track, because any that quietly withdraw before September 29 would signal that legal counsel has assessed the exposure as material. Also watch whether HHS issues guidance restricting official participation in events run by outside political groups, which would be the department clearest available response to the Hilliard statement.
Affected Tickers and Coins: GRAL, RMD, CMPS, CNC, WMT, HIMS, TEM, ELV, UNH
Source: Bloomberg
